GlassScriptPhysician profile
Jedd D Moore
NPI 1902380371
$1,937.33
in general payments reported to CMS, 2019-2025
20 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $1,451 · 2024: $133 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $337.30 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $277.69 | 2023 | Repatha |
| Glaxosmithkline, LLC. | $229.20 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $178.52 | 2023 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $158.50 | 2023 | |
| Idorsia Pharmaceuticals US INC | $149.14 | 2023 | Quviviq |
| Abbvie INC. | $107.58 | 2022-2024 | |
| Kite Pharma, INC. | $104.49 | 2025 | Yescarta |
| Tandem Diabetes Care, INC. | $102.09 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Boston Scientific Corporation | $57.44 | 2023 | Moses 550 D\F\L |
| Dexcom, INC. | $38.87 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $31.42 | 2023 | |
| Organon LLC | $28.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.99 | 2022-2023 | Farxiga |
| Mayne Pharma Commercial LLC | $25.53 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.34 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $17.48 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.46 | 2022 | |
| Lucid Diagnostics INC. | $16.13 | 2022 | |
| Astellas Pharma US INC | $14.14 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jedd Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.